Study of BB-031 in Acute Ischemic Stroke Patients (RAISE) - Trial NCT06226805
Access comprehensive clinical trial information for NCT06226805 through Pure Global AI's free database. This Phase 2 trial is sponsored by Basking Biosciences, Inc. and is currently Not yet recruiting. The study focuses on Acute Ischemic Stroke. Target enrollment is 156 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Basking Biosciences, Inc.
Timeline & Enrollment
Phase 2
Jun 01, 2024
Mar 01, 2027
Primary Outcome
Symptomatic Intracranial Hemorrhage (sICH)
Summary
The purpose of this study is to evaluate the safety and tolerability of ascending doses (Part
 A) and selected doses (Part B) of BB-031 in acute ischemic stroke patients presenting within
 24 hours of stroke onset.
 
 Participants will be randomized to receive one dose of either the investigational drug or
 placebo and will be followed for 90 days. A total of 156 patients are planned in this study.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06226805
Non-Device Trial